» Articles » PMID: 3264005

Cellular Aspects of Myasthenia Gravis

Overview
Journal Immunol Res
Date 1988 Jan 1
PMID 3264005
Authors
Affiliations
Soon will be listed here.
Abstract

Several cellular aspects were investigated in a large series of patients with MG. First, non-Ag-specific proliferation was tested by measuring the response to r-IL2. Thymocytes from most MG patients showed hyperactivity to r-IL2. Peripheral blood lymphocytes (PBL) from some patients also showed a high response to r-IL2. These responding patients were generally those tested before thymectomy, presenting a high anti-AChR Ab titer and a severe form of the disease. Second, Ag-specific proliferation of MG PBL was assayed using 8 synthetic peptides corresponding to selected domains of torpedo or human AChR. Only 2 peptides gave a positive response in a significant number of patients, essentially in those presenting high anti-AChR Ab titer. The first is located near the alpha-bungarotoxin binding site and the second is in a cytoplasmic domain, according to models predicting the AChR transmembrane orientation. The positive results were essentially obtained with the human peptides; the corresponding torpedo peptides were positive in very few patients. Both human and torpedo peptides which include a part of the alpha-bungarotoxin binding site were negative. Finally, although morphological abnormalities were clearly visible in thymic hyperplasia, no correlation could be established between the thymus type and the cellular proliferation either to r-IL2, or to the peptides. Overall, our data indicate that cell-dependent mechanisms participate in the pathogenesis of MG, but the level of their involvement deserves further investigation.

References
1.
Raimond F, Morel E, Bach J . Evidence for the presence of immunoreactive acetylcholine receptors on human thymus cells. J Neuroimmunol. 1984; 6(1):31-40. DOI: 10.1016/0165-5728(84)90040-7. View

2.
Draeger A, Swaak A, van den Brink H, Aarden L . T cell function in systemic lupus erythematosus: normal production of and responsiveness to interleukin 2. Clin Exp Immunol. 1986; 64(1):80-7. PMC: 1542159. View

3.
GENKINS G, Papatestas A, Horowitz S, Kornfield P . Studies in myasthenia gravis: early thymectomy. Electrophysiologic and pathologic correlations. Am J Med. 1975; 58(4):517-24. DOI: 10.1016/0002-9343(75)90125-4. View

4.
LE BRIGAND H, Levasseur P, Miranda A, Gaud C, WOJAKOWSKI I . [Surgical treatment of myasthenia by thymectomy. A report on 248 cases (author's transl)]. Ann Chir. 1980; 34(3):169-72. View

5.
Shoenfeld Y, Schwartz R . Immunologic and genetic factors in autoimmune diseases. N Engl J Med. 1984; 311(16):1019-29. DOI: 10.1056/NEJM198410183111605. View